Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$197.44 USD

197.44
4,182,372

-0.11 (-0.06%)

Updated Aug 26, 2024 04:00 PM ET

After-Market: $197.40 -0.04 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH

by Zacks Equity Research

J&J's (JNJ) initial data on CAR-T therapy candidate JNJ-68284528 from an early-stage study shows promising response rate.

Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio

by Zacks Equity Research

Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.

3 Top Dividend Stocks to Maximize Your Retirement Income - December 09, 2019

by Zacks Equity Research

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

J&J Stock Witnesses Volatility in '19: What to Expect in 2020

by Zacks Equity Research

Here we discuss the ups and downs of J&J's (JNJ) stock this year.

AbbVie (ABBV) Stock Moves -0.79%: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $87.04, moving -0.79% from the previous trading session.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - December 02, 2019

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

AbbVie (ABBV) Up 10.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Christopher Vargas headshot

3 Stocks for Value Investors to Buy as Market Reaches New High

by Christopher Vargas

The stock market closed at a record high today as the DJIA rose over 42 points and the S&P 500 gained 0.4%.

3 Top Dividend Stocks to Maximize Your Retirement Income - November 26, 2019

by Zacks Equity Research

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Timing the Market, Is it Possible? - November 25, 2019

by Zacks Equity Research

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to NVS' & AZN's Drugs, BMY-CELG Merger Closes

by Kinjel Shah

The FDA approves Novartis' (NVS) sickle cell disease candidate Adakveo and AstraZeneca's (AZN) Calquence for chronic lymphocytic leukemia. Bristol-Myers (BMY) completes $74 billion-buyout of Celgene.

Myovant Up on Successful Completion of Prostate Cancer Study

by Zacks Equity Research

Myovant's (MYOV) phase III study evaluating lead pipeline candidate, relugolix, in patients with advanced prostate cancer meets primary endpoint.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - November 20, 2019

by Zacks Equity Research

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Nalak Das headshot

5 Corporate Giants That Popped After Latest Earnings Release

by Nalak Das

A few corporate behemoths that reported their last earnings results less than five weeks ago, popped after releasing earnings results.

Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira

by Zacks Equity Research

The approval of Humira biosimilar is the fourth U.S. approval of a biosimilar product for Pfizer (PFE) in 2019.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

by Kinjel Shah

Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.

Kinjel Shah headshot

4 Big Drugmakers to Bet on After a Great Earnings Season

by Kinjel Shah

Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.

The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv

AbbVie Eyes Approval for Imbruvica+Rituxan in First-Line CLL

by Zacks Equity Research

AbbVie (ABBV) submits a regulatory application with the FDA seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan.

Mark Vickery headshot

Top Research Reports for Toyota, Netflix & AbbVie

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor (TM), Netflix (NFLX) and AbbVie (ABBV).

Zacks.com featured highlights include: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard Enterprise and Bristol-Myers Squibb

by Zacks Equity Research

Zacks.com featured highlights include: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard Enterprise and Bristol-Myers Squibb

Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View

by Zacks Equity Research

Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.

The Zacks Analyst Blog Highlights: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard and Bristol-Myers Squibb

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard and Bristol-Myers Squibb

Sanghamitra Saha headshot

Value Biotech ETFs & Stocks to Buy Now

by Sanghamitra Saha

Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.

ImmunoGen (IMGN) Q3 Earnings & Sales Beat, Shares Rally

by Zacks Equity Research

ImmunoGen (IMGN) reports narrower-than-expected third-quarter loss and beats revenue estimates. The company is set to initiate the FDA recommended phase III study on mirvetuximab soravtansine by year-end.